Antineoplastic Agents: Cytotoxic Agents: Miscellaneous
IEYLE1 “Eylea aflibercept (rch) 40 mg/mL solution for intravitreal injection” 40 mg/ml; 0.05 ml/vial
IZALT1 “Zaltrap 25mg/ml concentrate for solution for infusion” 25 mg/ml; 4ml/vial
適應症：
IEYLE1：適用於治療血管新生型(濕性)年齡相關性黃斑部退化病變。中央視網膜靜脈阻塞(CRVO)續發黃斑部水腫所導致的視力損害。 糖尿病黃斑部水腫(DME)所導致的視力損害。分支視網膜靜脈阻塞(BRVO)續發黃斑部水腫所導致的視力損害。
IZALT1：與5-fluorouracil、leucovorin、irinotecan-(FOLFIRI)合併使用，治療已使用含有oxaliplatin化學療法無效或惡化之轉移性大腸直腸癌病患。
Usual dose:
Central retinal vein occlusion with macular edema: 2 mg (0.05 mL) by INTRAVITREAL injection once every 4 weeks (monthly); adequate anesthesia and a topical broad-spectrum microbicide should be given prior to the injection.
Exudative age-related macular degeneration: 2 mg (0.05 mL) INTRAVITREAL injection every 4 weeks for 12 weeks, then once every 8 weeks; adequate anesthesia and a topical broad-spectrum microbicide should be given prior to the injection.
Colorectal cancer, metastatic: IVD>1hr, 4mg/kg q2W
Precautions:
Monitor for signs and symptoms of GI and other severe bleeding events. Do not administer to patients with severe hemorrhage.
Adverse effect:
Common: cataract, conjunctival hemorrhage, conjunctival hyperemia, corneal erosion, pain in eye, raised intraocular pressure, vitreous detachment, vitreous floaters.
Serious: arterial thrombosis, hypersensitivity reaction, endophthalmitis, retinal detachment, retinal tear.